Table 2.

Dosing, consumption and bleeding rates with rIX-FP prophylaxis and prior FIX product prophylaxis in patients with haemophilia B in Italy, Belgium and the UK

	Italy		Belgium		UK
	rIX-FP (n = 44)	Prior FIX (n = 44)	rIX-FP (n = 7)	Prior FIX (n = 7)	rIX-FP (n = 22)	Prior FIX (n = 22)
Dose, IU/kg/week	38.6 ± 16.5	84.4 ± 34.4	30.3 ± 11.5	103.1 ± 60.9	29.2 ± 8.5	71.7 ± 18.9
ABR	0.2 ± 0.4	3.5 ± 5.7	0.4 ± 0.8	6.6 ± 3.4	1.0 ± 0.9	3.1 ± 1.4
AsBR	0.02 ± 0.2	0.7 ± 1.0	0.0 ± 0.0	3.0 ± 3.3	0.4 ± 0.6	2.0 ± 1.5
Patients with zero bleeds, %	84.1	13.6	71.4	14.3	36.4	0.0
Patients with zero spontaneous bleeds, %	97.7	50.0	100.0	42.9	63.6	22.7

Data are presented as mean ± SD unless otherwise stated

ABR, annualised bleeding rate; AsBR, annualised spontaneous bleeding rate; SD, standard deviation